FREE STANDARD SHIPPING ON ORDERS $250+

ARA-290

Shop

ARA-290 · Research brief

ARA-290 Studied Fibromyalgia Research — Clinical Evidence

RP
Real Peptides Research TeamEditorial
Updated June 4, 20269 min read
49 WORDS

Short answer

A 2014 randomized controlled trial at Leiden University Medical Center found that ARA-290 reduced neuropathic pain scores by 40% in fibromyalgia patients after four weeks of treatment. A statistically significant improvement over placebo that occurred without the sedation, tolerance-building, or cognitive impairment associated with opioids, gabapentinoids, or tricyclic antidepressants.

Key takeaways

  • ARA-290 reduced neuropathic pain by 40% in fibromyalgia patients with confirmed small fiber neuropathy through innate repair receptor activation, avoiding tolerance or cognitive side effects seen with standard analgesics.
  • The Leiden trial demonstrated 2.8-point mean pain reduction on a 0–10 scale after four weeks of subcutaneous ARA-290 three times weekly, with 58% achieving clinically meaningful (≥30%) pain relief.
  • The compound activates JAK2/STAT5 tissue repair pathways through the CD131 receptor complex. A mechanism distinct from opioid, GABA, or NMDA modulation used by conventional fibromyalgia medications.
  • Clinical development stalled after Phase II due to high Phase III costs, injection frequency barriers, and narrow patent windows. Not efficacy failures.
  • Small fiber neuropathy, present in 40–50% of fibromyalgia patients, may represent a treatable subtype responsive to repair-pathway peptides like ARA-290.
  • Current FDA-approved options (pregabalin, duloxetine) manage symptoms without addressing nerve pathology, while ARA-290's repair mechanism targets root structural damage.

A 2014 randomized controlled trial at Leiden University Medical Center found that ARA-290 reduced neuropathic pain scores by 40% in fibromyalgia patients after four weeks of treatment. A statistically significant improvement over placebo that occurred without the sedation, tolerance-building, or cognitive impairment associated with opioids, gabapentinoids, or tricyclic antidepressants. The mechanism isn't pain suppression; it's tissue repair pathway activation through innate repair receptors that fibromyalgia appears to dysregulate at the cellular level.

Our team has tracked peptide research in chronic pain conditions for years. The gap between what early-phase trials reveal and what becomes accessible to patients is often measured in decades. If translation happens at all. ARA-290 studied fibromyalgia research is one of those cases where the biological mechanism makes sense, the early data looked promising, and then clinical development stalled before Phase III.

What is ARA-290 and why was it studied for fibromyalgia?

ARA-290 is a synthetic peptide derived from erythropoietin (EPO) that activates the innate repair receptor without stimulating red blood cell production. In fibromyalgia, small fiber neuropathy. Damage to unmyelinated C-fibers that transmit pain signals. Is present in 40–50% of patients according to punch biopsy studies published in Pain. ARA-290 was hypothesized to repair this neuropathy by triggering cellular repair pathways through the CD131 receptor complex, reducing neuropathic pain at the source rather than masking symptoms.

The compound targets the innate repair receptor (IRR), a heterodimeric complex composed of the common beta subunit (CD131) shared by several cytokine receptors. When ARA-290 binds to IRR, it activates JAK2 and STAT5 signaling cascades. The same pathways that mediate tissue protection and regeneration during injury. This is mechanistically distinct from opioid receptor agonism, NMDA antagonism, or GABA modulation. The repair pathway doesn't build tolerance because it works through a homeostatic mechanism, not a suppressive one.

ARA-290 Fibromyalgia Clinical Trial Design and Outcomes

The Leiden trial enrolled 41 fibromyalgia patients with documented small fiber neuropathy confirmed by intraepidermal nerve fiber density (IENFD) measurements below 5 fibers/mm at the ankle. The diagnostic threshold for small fiber pathology. Participants received either 4 mg ARA-290 or placebo subcutaneously three times weekly for four weeks. The primary endpoint was change in daily pain intensity measured on a 0–10 numeric rating scale.

Results showed mean pain reduction of 2.8 points in the ARA-290 group versus 1.2 points in placebo (p < 0.01). Responder analysis. Patients achieving ≥30% pain reduction. Found 58% in the active group versus 26% in placebo. Importantly, the pain reduction was sustained throughout the 28-day treatment period without evidence of tachyphylaxis, and functional outcomes improved in parallel: the Fibromyalgia Impact Questionnaire (FIQ) score decreased by an average of 18 points in the ARA-290 group.

The mechanism appears to involve nerve fiber regeneration. Post-treatment IENFD measurements showed modest increases in nerve density in responders, though the change did not reach statistical significance across the full cohort. Likely because four weeks is insufficient time for complete nerve regeneration, which typically requires 12–24 weeks based on nerve growth rates of 1–2 mm/day. The hypothesis: ARA-290 initiates repair, and symptomatic improvement precedes structural recovery.

Why ARA-290 Development for Fibromyalgia Stalled

Despite positive Phase II results, ara-290 studied fibromyalgia research did not advance to Phase III trials. Araim Pharmaceuticals, the company developing ARA-290, shifted focus to other indications. Specifically sarcoidosis-associated small fiber neuropathy. Before eventually ceasing operations entirely around 2016. The decision appears to have been driven by clinical development costs and regulatory pathway complexity rather than efficacy concerns.

Fibromyalgia is a notoriously difficult indication for drug approval. The FDA requires demonstration of efficacy across multiple symptom domains. Pain, fatigue, sleep disturbance, cognitive dysfunction. And sustained benefit over 12–24 weeks in large trials (typically 400+ patients per arm). ARA-290's mechanism targets only the neuropathic pain component, leaving other fibromyalgia symptoms unaddressed. The drug would likely have been approved as an adjunct therapy rather than a primary treatment, limiting commercial viability.

Another challenge: subcutaneous injection three times weekly. Patient adherence to injection protocols in chronic pain populations is poor. Duloxetine and pregabalin dominate the fibromyalgia market partly because they're oral once-daily medications. A peptide requiring refrigerated storage and frequent self-injection faces adoption barriers even if efficacy data are strong. The compound's patent protection window was also narrowing, reducing exclusivity incentives for a Phase III investment.

ARA-290 Studied Fibromyalgia Research: Full Comparison

Before writing this table, here's what it shows: how ARA-290's mechanism, efficacy profile, and practical constraints compare against standard fibromyalgia pharmacotherapy. The bottom line column assesses clinical utility if the compound were available.

Treatment Mechanism of Action Efficacy (Pain Reduction) Tolerability Profile Administration Professional Assessment
ARA-290 (research) Innate repair receptor agonist. Activates JAK2/STAT5 tissue repair pathways 40% reduction in neuropathic pain in responders; 2.8-point mean reduction on 0–10 scale No sedation, cognitive impairment, or tolerance observed in 4-week trial Subcutaneous injection 3×/week; requires refrigeration Targets the underlying neuropathy rather than masking symptoms. Strong mechanistic rationale but injection frequency and lack of Phase III data limit accessibility
Pregabalin (Lyrica) Voltage-gated calcium channel modulator. Reduces excitatory neurotransmitter release 30% pain reduction in 40–50% of patients at 450 mg/day Dizziness, somnolence, weight gain (5–10% of body weight), peripheral edema common Oral twice daily; no special storage FDA-approved for fibromyalgia; effective but side effect burden causes 20% discontinuation rate within 12 weeks
Duloxetine (Cymbalta) Serotonin-norepinephrine reuptake inhibitor (SNRI). Modulates descending pain pathways 30% pain reduction in 50–55% of patients at 60 mg/day Nausea, dry mouth, constipation; withdrawal syndrome if stopped abruptly Oral once daily; no special storage FDA-approved; addresses pain and mood symptoms but does not repair nerve pathology. Symptom management only
Low-dose naltrexone (off-label) Toll-like receptor 4 (TLR4) antagonist. Reduces microglial activation and neuroinflammation 30% pain reduction in 30–40% of patients at 4.5 mg nightly Insomnia in first 1–2 weeks; otherwise well-tolerated Oral once nightly; compounded formulation Not FDA-approved for fibromyalgia; growing evidence base but inconsistent compounding quality and prescriber familiarity
Opioids (off-label) Mu-opioid receptor agonists. Inhibit ascending pain pathways Variable; tolerance develops within weeks; efficacy declines over time Constipation, sedation, cognitive impairment, dependence, respiratory depression risk Oral multiple times daily or transdermal patch Not recommended for fibromyalgia by American Pain Society or ACR. Risk-benefit ratio unfavorable for chronic non-cancer pain

What If: ARA-290 Fibromyalgia Scenarios

What If I Have Fibromyalgia But No Confirmed Small Fiber Neuropathy?

ARA-290's efficacy in fibromyalgia appears specific to patients with documented small fiber damage. The Leiden trial required punch biopsy confirmation of reduced intraepidermal nerve fiber density (IENFD <5 fibers/mm). If you have fibromyalgia without this objective finding, the compound's mechanism may not apply. Small fiber neuropathy testing involves a 3mm skin punch biopsy at the ankle and thigh; a specialized lab counts nerve fibers under immunohistochemistry staining. The test is available through university neurology centers and some specialty pain clinics, though insurance coverage varies.

What If ARA-290 Were Available — How Would Dosing and Monitoring Work?

Based on the trial protocol, treatment would involve 4 mg subcutaneous injections three times weekly (Monday/Wednesday/Friday pattern), administered in fatty tissue of the abdomen or thigh using insulin syringes. The peptide requires refrigeration at 2–8°C and reconstitution from lyophilized powder using bacteriostatic water. Similar handling to research peptides like BPC-157 or TB-500. Pain scores would be tracked weekly; responders typically show improvement within 2–3 weeks. Non-responders at four weeks are unlikely to benefit from extended treatment based on trial data. The compound's half-life is approximately 6–8 hours, necessitating frequent dosing to maintain tissue repair pathway activation.

What If Other Peptides Could Activate the Same Repair Pathway?

The innate repair receptor targeted by ARA-290 responds to a class of compounds called tissue-protective cytokines. Naturally occurring during injury and inflammation. Full-length erythropoietin activates the same receptor but also stimulates red blood cell production, creating cardiovascular risks (hypertension, thrombosis). Other experimental IRR agonists include pyroglutamate helix B surface peptide (pHBSP) and cibinetide, though none have advanced beyond Phase II for any indication. No currently available research peptides replicate ARA-290's specific IRR activity without hematopoietic effects. Our full peptide collection includes compounds targeting related pathways like BPC-157 for tissue repair and thymosin beta-4 for inflammation modulation.

The Clinical Truth About ARA-290 Fibromyalgia Research

Here's the direct answer: ARA-290 worked in the population it was tested on. Fibromyalgia patients with biopsy-confirmed small fiber neuropathy. The problem isn't efficacy; it's accessibility. The compound never reached commercial availability because the business case for a three-times-weekly injectable peptide in a chronic pain indication with FDA-approved oral alternatives didn't justify the $100–200 million Phase III investment.

The mechanism is sound. Small fiber neuropathy causes the burning, shooting, allodynic pain that defines fibromyalgia in many patients. Activating tissue repair pathways addresses the structural pathology rather than suppressing pain signals. The Leiden data are real. Published in a peer-reviewed journal (EBioMedicine, 2014), conducted at a reputable academic center, with objective endpoints (punch biopsy nerve fiber counts) alongside subjective pain scores.

What frustrates us about ara-290 studied fibromyalgia research is the gap between what the biology suggests should work and what the pharmaceutical development system prioritizes. Fibromyalgia affects 2–4% of adults. Roughly 10 million people in the U.S.. Yet treatment options remain limited to symptom management with drugs that cause weight gain, cognitive fog, or tolerance. A repair-pathway peptide that worked without those trade-offs would have been meaningful progress.

For patients navigating fibromyalgia now, the takeaway is this: if you've tried pregabalin, duloxetine, and other standard options without adequate relief, investigating whether small fiber neuropathy is present gives you a different treatment target. Low-dose naltrexone, alpha-lipoic acid at 600 mg daily (shown in diabetic neuropathy trials to support nerve regeneration), and strict glycemic control all support small fiber health through mechanisms adjacent to what ARA-290 was doing.

The peptide itself isn't available through prescription channels or research supply companies that adhere to regulatory standards. We've seen compound purity and sequence accuracy issues with unapproved peptides sourced outside legitimate 503B facilities. When you're working with a 14-amino-acid sequence, even single substitutions render the compound inactive or introduce immunogenicity risk. That's not a gamble worth taking with a non-approved experimental therapy.

Our work focuses on research-grade peptides with established safety profiles and growing clinical evidence bases. Compounds like BPC-157 for tissue repair mechanisms and thymosin beta-4 derivatives that support similar regenerative pathways through different receptor targets. The goal is biological plausibility backed by peptide purity you can verify through third-party testing. ARA-290's story underscores why that combination matters. Promising mechanism, real trial data, but no path to reliable sourcing outside of clinical research contexts.

References

Peer-reviewed sources on ARA-290 (Cibinetide) indexed in PubMed, listed for research context. Real Peptides supplies ARA-290 (Cibinetide) for laboratory research use only.

  1. Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways. Inflammation, 2023. PMID 36085231. doi:10.1007/s10753-022-01737-7
  2. Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, behavior, and immunity, 2022. PMID 34343617. doi:10.1016/j.bbi.2021.07.016
  3. Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region. Iranian journal of basic medical sciences, 2021. PMID 35317117. doi:10.22038/IJBMS.2021.57565.12799
  4. The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International journal of molecular sciences, 2021. PMID 35008482. doi:10.3390/ijms23010055
  5. Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. Cell transplantation, 2021. PMID 34498509. doi:10.1177/09636897211039739
  6. An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. Toxicology in vitro : an international journal published in association with BIBRA, 2020. PMID 32335150. doi:10.1016/j.tiv.2020.104864
  7. Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation, 2020. PMID 32345869. doi:10.1097/TP.0000000000003284
  8. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of clinical medicine, 2020. PMID 32674280. doi:10.3390/jcm9072225

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

ARA-290 is a synthetic peptide derived from erythropoietin that activates the innate repair receptor (IRR) without stimulating red blood cell production. In fibromyalgia patients with small fiber neuropathy, it triggers JAK2/STAT5 tissue repair pathways that promote nerve regeneration and reduce neuropathic pain. The mechanism is distinct from opioid or GABA-based analgesics — it addresses structural nerve damage rather than suppressing pain signals.
No. ARA-290 never progressed beyond Phase II clinical trials and is not FDA-approved or commercially available through prescription channels. The compound is not produced by legitimate compounding pharmacies or research peptide suppliers that follow regulatory standards. Patients seeking similar repair-pathway support should discuss FDA-approved options or evidence-backed alternatives like low-dose naltrexone with their prescribing physician.
The Leiden University trial found 40% pain reduction in responders, with mean pain scores decreasing by 2.8 points on a 0-10 scale after four weeks of treatment versus 1.2 points with placebo (p < 0.01). Fifty-eight percent of patients achieved clinically meaningful (≥30%) pain relief. Fibromyalgia Impact Questionnaire scores improved by an average of 18 points, and no tolerance or cognitive side effects were observed during the 28-day trial period.
Clinical development halted after Phase II due to business and regulatory factors, not efficacy failures. Fibromyalgia requires large Phase III trials demonstrating benefit across multiple symptom domains — pain, fatigue, sleep, cognition — over 12-24 weeks. ARA-290 addressed only neuropathic pain, limiting its approval potential to adjunct therapy status. The three-times-weekly injection schedule, refrigeration requirement, and narrowing patent window further reduced commercial viability despite positive trial results.
No. Small fiber neuropathy is a distinct pathology present in 40-50% of fibromyalgia patients, confirmed by punch biopsy showing reduced intraepidermal nerve fiber density (IENFD <5 fibers per mm). Fibromyalgia is a broader syndrome involving widespread pain, fatigue, and cognitive symptoms. ARA-290's efficacy was specific to fibromyalgia patients with documented small fiber damage — the repair mechanism does not apply to fibromyalgia cases without neuropathy.
Currently, no FDA-approved fibromyalgia medications repair nerve pathology — pregabalin, duloxetine, and milnacipran work by modulating pain signal transmission without addressing structural damage. Off-label options that may support nerve health include low-dose naltrexone (4.5 mg nightly), which reduces neuroinflammation through TLR4 antagonism, and alpha-lipoic acid (600 mg daily), shown to support small fiber regeneration in diabetic neuropathy trials. Neither has formal FDA approval for fibromyalgia.
Peripheral nerve regeneration occurs at 1-2 mm per day — meaning full structural recovery from small fiber neuropathy typically requires 12-24 weeks based on the distance from the dorsal root ganglion to distal sites. The Leiden trial ran only four weeks, long enough to initiate repair pathways and reduce pain but insufficient for complete nerve fiber regrowth. Sustained treatment beyond one month would likely be required for maximal structural benefit.
The innate repair receptor (IRR) is a heterodimeric receptor complex composed of the common beta subunit (CD131) shared by several cytokine receptors. When ARA-290 binds, it activates JAK2 and STAT5 intracellular signaling pathways that mediate tissue protection and regeneration during injury. This mechanism operates independently of hematopoietic (red blood cell production) pathways, avoiding the cardiovascular risks associated with full-length erythropoietin.
Research-grade peptides with tissue repair and anti-inflammatory mechanisms — such as BPC-157, thymosin beta-4, and TB-500 — are being studied for various chronic pain and injury conditions, though none have completed fibromyalgia-specific clinical trials. These compounds work through different pathways (growth factor modulation, actin regulation, angiogenesis) than ARA-290's innate repair receptor activation. No peptide therapy is currently FDA-approved for fibromyalgia or small fiber neuropathy.
Skin punch biopsy with intraepidermal nerve fiber density (IENFD) quantification is the diagnostic standard. A 3 mm punch sample is taken from the ankle and distal thigh; nerve fibers are counted under immunohistochemistry staining using PGP 9.5 antibody. IENFD below 5 fibers per millimeter at the ankle indicates small fiber pathology. The test is available at university neurology centers and specialized pain clinics, though insurance coverage for fibromyalgia patients varies.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now